Xiangming Meng

Dr. Xiangming Meng

Wuxi Huishan District People's Hospital
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
Xiangming MengXiangming Meng
Xiangming Meng
YDYanzhong Deng
Yanzhong Deng
ZDZhiyong Dai
Zhiyong Dai
ZMZhisheng Meng
Zhisheng Meng

28 April 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
Xiangming MengXiangming Meng
Xiangming Meng
JWJing Wang
Jing Wang
JSJian Sun
Jian Sun
KZKangxu Zhu
Kangxu Zhu
A growing body of evidence suggests that patients with the 2019 Coronavirus disease (COVID-19) have a risk of developing sudden sensorineural hearing loss (SSNHL). The pathogenesis of COVID-19-related SSNHL remains unclear. This systematic review examined whether COVID-19 causes an increased incidence of SSNHL and the clinical characteristics of patients with COVID-19-related SSNHL according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. SSNHL usually developed between a few days and 2 months after the diagnosis of COVID-19, and a proportion of patients developed it before the diagnosis of COVID-19. The literature is inconsistent regarding whether COVID-19 causes an increased incidence of SSNHL, and this matter remains unclear. This review included 23 patients with COVID-19-related SSNHL, all adult patients with an average age of 43.1 years. Of these patients, 60.9% had accompanying tinnitus symptoms. Glucocorticoids are the preferred medication to treat COVID-19-related SSNHL. Intratympanic administration may be considered to reduce the side effects of the drug. Hearing tests are suggested when hearing loss is suspected in COVID-19 individuals, and if SSNHL is detected, prompt and aggressive treatment is vital. Large-scale, multicenter research on the pathophysiology, treatment, and prognosis of COVID-19- related SSNHL should be conducted in the future.

1 November 2003 in Genomics
Verified
Journal Article
Closed access
CYChuan Yu
Chuan Yu
Xiangming MengXiangming Meng
Xiangming Meng
SZShanfang Zhang
Shanfang Zhang
GZGuoping Zhao
Guoping Zhao
LHLandian Hu
Landian Hu
XKXiangyin Kong
Xiangyin Kong

1 May 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
Xiangming MengXiangming Meng
Xiangming Meng
ZDZhiyong Dai
Zhiyong Dai
CHChao Hang
Chao Hang
YWYangyang Wang
Yangyang Wang

29 September 2021 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
Xiangming MengXiangming Meng
Xiangming Meng
YPYuandan Pan
Yuandan Pan
Objectives: The pandemic has affected over 182 million coronavirus disease 2019 (COVID-19) cases worldwide. Accumulated evidence indicates that anosmia is one of the significant characteristics of COVID-19 with a high prevalence. However, many aspects of COVID-19-induced anosmia are still far from being fully understood. The purpose of this review is to summarize recent developments in COVID-19-induced anosmia to increase awareness of the condition. Methods: A literature search was carried out using the PubMed, Embase, Web of Science, and Scopus. We reviewed the latest literature on COVID-19-induced anosmia, including mechanisms of pathogenesis, olfactory testing, anosmia as predictive tool, pathological examinations, imaging findings, affected factors, co-existing diseases, treatments, prognosis, hypothesis theories, and future directions. Results: The possible pathogenesis of COVID-19-induced anosmia may involve inflammation of the olfactory clefts and damage to the olfactory epithelium or olfactory central nervous system by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The D614G spike variant may also play a role in the increased number of anosmia patients. Anosmia may also be an essential indicator of COVID-19 spread and an early indicator of the effectiveness of political decisions. The occurrence and development of COVID-19-induced anosmia may be influenced by smoking behaviors and underlying diseases such as type 2 diabetes, gastroesophageal disorders, and rhinitis. Most patients with COVID-19-induced anosmia can fully or partially recover their olfactory function for varying durations. COVID-19-induced anosmia can be treated with various approaches such as glucocorticoids and olfactory training. Conclusion: Anosmia is one of the main features of COVID-19 and the underlying disease of the patient may also influence its occurrence and development. The possible pathogenesis of COVID-19-induced anosmia is very complicated, which may involve inflammation of the olfactory clefts and damage to the olfactory epithelium or olfactory central nervous system.

2 June 2022 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
Xiangming MengXiangming Meng
Xiangming Meng
KZKangxu Zhu
Kangxu Zhu
JWJing Wang
Jing Wang
PLPan Liu
Pan Liu